Publication: Evaluation of Optical Radiation from Visual Pathways with Diffusion Tensor Imaging in Patients with Neurofibromatosis Type 1
Program
Authors
Authors
ÇEŞME, DİLEK HACER
Advisor
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Objective: It was investigated whether patients with
neurofibromatosis type 1 (NF1) with and without optic glioma
(OG) differed from the healthy control group in terms of diffusion
tensor imaging (DTI) parameters obtained from optic radiation.
Methods: Eighty three patients and 36 healthy controls followed
with the diagnosis of NF1 were included in the study. Routine
MRI and DTI were applied to all subjects. Fractional anisotropy
(FA), mean diffusity (MD), radial diffusity (RD) and axial diffusity
(AD) values were calculated by placing ROI on the right and left
optic radiation on colored FA maps. Patients with OG detected by
conventional magnetic resonance imaging (n=19) were classified as
group 1, patients with NF1 without OG (n=64) were classified as
group 2 and they were compared with the healthy control group in
terms of DTI parameters.
Results: The right and left optic radiation FA values of the patients
in group 1 and group 2 were significantly different when compared
with the healthy control group. Optical radiation FA values were
significantly lower than healthy control group. MD values in group
1 patients with OG were significantly higher than healthy control
group. Optic radiation RD values were significantly higher in group
1 and group 2 compared with healthy control group.
Conclusion: There appears to be microstructural damage in optic
radiation in patients with NF1 with or without OG. The idea that changes in FA values detected in optic radiation in visual pathways
in patients with NF1 can be predicted in the early period of visual
impairment is promising in terms of treatment planning and
management.
Description
Source:
Keywords:
Citation
ÇEŞME D. H. , -Evaluation of Optical Radiation from Visual Pathways with Diffusion Tensor Imaging in Patients with Neurofibromatosis Type 1-, BEZMIALEM SCIENCE, cilt.9, sa.4, ss.382-386, 2021